Recommended Articles
Deals & Exits

India's Healthcare IPO Pipeline Is Running Hot: Hospitals and Medtech Are the New Listing Sweet Spot

By Angeled · October 18, 2026 · Deals & Exits
India's Healthcare IPO Pipeline Is Running Hot: Hospitals and Medtech Are the New Listing Sweet Spot
India's Healthcare IPO Pipeline Is Running Hot: Hospitals and Medtech Are the New Listing Sweet Spot

Thesis: Two healthcare IPOs hitting the Indian market within days of each other — Paras Healthcare's ₹1,450 crore hospital listing and Sahajanand Medical Technologies' ₹475.5 crore medtech offering — confirm that hospitals and medical devices have become India's new listing sweet spot. With defense IPOs (like Tonbo Imaging's ₹852.2 crore offering, covered in our October 16 anchor-book article) already demonstrating hot primary-market demand, healthcare is riding the same wave. Founders should understand why these listings work now, how IPO mechanics shape outcomes, and what the window means for their own timing.

The news

Paras Healthcare opens October 21 and closes October 23, 2026 — a ₹1,450 crore book-built issue comprising a ₹500 crore fresh issue and a ₹950 crore offer for sale, at a price band of ₹660–₹693 per share. It lists on BSE and NSE on October 28, with allotment on October 26 and anchor bidding on October 19. The reservation split is 75% QIB, 15% NII (HNI), and 10% retail. Founded in 1987, Paras is the fifth-largest healthcare provider across North India, Bihar, and Jharkhand, running 8 hospitals under the Paras Health brand, focused on affordable care in tier-2 and tier-3 cities. Bed capacity grew from 1,250 (March 2022) to 2,135 (March 2024). Financials: revenue ₹1,628.79 crore in FY2026 (vs ₹1,314.21 crore in FY2025), PAT of ₹43.83 crore against a ₹57.99 crore loss in FY2025 — a genuine turnaround. IPO proceeds target debt repayment: ₹320.90 crore of company borrowings plus ₹54.10 crore via its Srinagar subsidiary.

Sahajanand Medical Technologies (SMT) opened October 15 and closes October 19 — a ₹475.5 crore issue at a price band of ₹327–₹344, with allotment October 21 and listing October 23 on BSE and NSE. The split here is 50% QIB, 15% NII, and a notably larger 35% retail quota. Founded in 2001, SMT is a medical-device maker focused on Class III vascular and structural-heart intervention devices — drug-eluting stents (it was the first globally to achieve CE certification for a biodegradable-polymer DES, Infinnium), TAVI valves, and occluders — sold in over 76 countries. Financials show steady growth: revenue ₹1,218.73 crore and PAT ₹69.08 crore in FY2026, up from ₹908.59 crore revenue and ₹7.35 crore PAT in FY2024.

Why healthcare IPOs are listing now

Three forces are converging:

  1. A proven primary-market window. Tonbo Imaging's ₹852.2 crore IPO earlier this month (see our October 16 anchor-book article) showed deep institutional appetite. Bankers move where demand is demonstrated.
  2. Healthcare's defensive growth story. Hospitals offer annuity-like cash flows tied to rising insurance penetration and tier-2/3 demand; medtech offers export-led manufacturing growth aligned with the "Make in India" device story. In volatile markets, that combination of defensiveness and growth is exactly what IPO investors pay up for.
  3. Turnaround and scale narratives. Paras flipped from a ₹58 crore loss to a ₹44 crore profit in a year while expanding beds 70% in two years. SMT tripled PAT over two years while selling into 76 countries. IPOs need a story arc, and both companies have one.

IPO mechanics, decoded for founders

The reservation splits tell you who each listing is for. Paras's 75% QIB / 15% NII / 10% retail split is a classic institutional-heavy hospital IPO: QIBs (qualified institutional buyers — mutual funds, insurers, foreign investors) anchor the book, and a small retail quota keeps listing-day volatility manageable. SMT's 50% QIB / 15% NII / 35% retail split leans harder on retail participation — a bigger retail base can support listing-day momentum but also amplifies volatility.

The price band is the range within which investors bid; final pricing reflects discovered demand. The fresh issue vs. offer for sale distinction matters: Paras's ₹500 crore fresh issue brings new capital in (mostly for deleveraging), while the ₹950 crore OFS is existing shareholders cashing out — investors read heavy OFS as an exit, not a growth raise.

Anchor bidding (Paras: October 19) lets institutions commit before the public offer, signaling confidence — strong anchor demand is the best predictor of listing-day performance.

The counterargument: thin margins, high expectations

Hospital economics are unforgiving. Paras's PAT margin is just 2.69% on FY2026 numbers, with a debt-to-equity ratio of 3.53 — the IPO is substantially a deleveraging exercise. SMT's 5.71% PAT margin is healthier but still thin for a "technology" story. Peer P/E multiples are demanding: Apollo Hospitals at ~60x, Max Healthcare at ~64x, KIMS at ~125x earnings. These listings are priced for flawless execution — any stumble gets punished quickly.

The founder takeaway

The window is open, but it is selective. India's IPO market rewards demonstrated profitability or a credible near-term path to it, a growth story tied to structural demand, and institutional-grade governance. Pre-revenue founders should not read these listings as permission — the market is paying for turnarounds and scale, not promises.

Prepare the balance sheet before the roadshow. Paras is using its IPO to fix leverage; smarter to fix it a year earlier and list from strength. Clean up debt, related-party transactions, and promoter holdings well before filing — the DRHP process magnifies every blemish.

Retail is a strategic choice, not a default. SMT's 35% retail quota courts public enthusiasm; Paras's 10% courts institutional stability. Founders should decide which shareholder base they want to live with for the next decade, because the IPO's reservation structure shapes it.

Angeled.com connects founders building in healthcare and life sciences with investors who understand how to time and structure a public listing.

Read Next